Mesenchymal tumor cells drive adaptive resistance of Trp53-/- breast tumor cells to inactivated mutant Kras.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular oncology"
DOI: 10.1002/1878-0261.13220
Abstract: As precision medicine increases the response rate of treatment, tumors frequently bypass inhibition and reoccur. In order for treatment to be effective long term, the mechanisms enabling treatment adaptation need to be understood. Here, we… read more here.
Keywords: treatment; tumor cells; krasg12d; trp53 breast ... See more keywords